Since Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) and Ra Pharmaceuticals Inc. (NASDAQ:RARX) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations of both companies.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aeglea BioTherapeutics Inc.	5.37M	38.90	35.93M	-1.88	0.00
Ra Pharmaceuticals Inc.	N/A	0.00	63.89M	-2.27	0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Aeglea BioTherapeutics Inc. and Ra Pharmaceuticals Inc.

Profitability

Table 2 has Aeglea BioTherapeutics Inc. and Ra Pharmaceuticals Inc.’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aeglea BioTherapeutics Inc.	-669.09%	-62.1%	-56%
Ra Pharmaceuticals Inc.	0.00%	-72.3%	-64.8%

Liquidity

Aeglea BioTherapeutics Inc. has a Current Ratio of 9.4 and a Quick Ratio of 9.4. Competitively, Ra Pharmaceuticals Inc.’s Current Ratio is 10.3 and has 10.3 Quick Ratio. Ra Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Aeglea BioTherapeutics Inc.

Insider and Institutional Ownership

The shares of both Aeglea BioTherapeutics Inc. and Ra Pharmaceuticals Inc. are owned by institutional investors at 72.9% and 77% respectively. Aeglea BioTherapeutics Inc.’s share owned by insiders are 1.1%. On the other hand, insiders owned about 5.62% of Ra Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Aeglea BioTherapeutics Inc.	-6.89%	-13.66%	-10.19%	-21.52%	59.67%	44.92%
Ra Pharmaceuticals Inc.	11.73%	27.68%	40.85%	110.51%	129.73%	107.29%

For the past year Aeglea BioTherapeutics Inc.’s stock price has smaller growth than Ra Pharmaceuticals Inc.

Summary

On 6 of the 9 factors Aeglea BioTherapeutics Inc. beats Ra Pharmaceuticals Inc.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. Its human enzymes are designed to degrade specific amino acids in the blood. The companyÂ’s lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies. Its pipeline of engineered human enzyme product candidates in preclinical development includes AEB3103, an enzyme that degrades the amino acids cysteine to target cancer to oxidative stress; AEB2109, an enzyme that degrades the amino acid methionine to target methionine dependent cancers; and AEB4104, an engineered human enzyme to treat another inborn errors of metabolism by degrading the amino acid homocysteine. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea Biotherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The companyÂ’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP). The companyÂ’s preclinical testing products include Factor D inhibition for age-related macular degeneration and geographic atrophy, as well as for Orphan renal dense deposit and C3 glomerulonephritis; Oral C5 inhibitor for PNH, rMG, LN, and central nervous system (CNS) diseases; and C1s inhibition for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.